Damage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy.

Moreover, the ORR of PD-1 inhibitors applied to MPM patients of two separate subtypes in the validation cohort did not reach statistical significance, although there was a trend that implied patients belonging to the inflammatory subtype benefit more from ICIs and the DCR, probably on account of small sample size or limited efficacy of ICIs as a single agent in MPM.

also in 111,027 other papers